Vishram-Nielsen, Julie K. K.
Tomasoni, Daniela
Gustafsson, Finn
Metra, Marco
Article History
Accepted: 16 December 2021
First Online: 3 February 2022
Declarations
:
: No external funds were userd in the preparation of this invited manuscript.
: FG reports consulting fees from Abbott, Pfizer, Bayer, Ionis, Alnylam, Boehringer-Ingelheim, and speakers fees from Novartis, AstaZeneca, Orion Pharma. MM reports consulting fees from Actelion, Amgen, Astra-Zeneca, Abbott vascular, Bayer, Servier, Edwards Therapeutics, Livanova, Vifor pharma, WindTree Therapeutics, as member of Trials’ Committees or Advisory Boards or for speeches at sponsored meetings in the last three years.
: Manuscript was written by JV, FG, DT, and MM. All the authors have participated to enhance the quality of the paper. All of them met the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this paper, take the full responsibility for the integrity of the work as a whole, and have given their approval for this final version to be published.
: This article is based on previously conducted studies and does not contain any studies with human participants or animal performed by the authors without a previous Ethics Committee approval.
: All the authors have contributed to review and enhancement of the quality of the paper and have reviewed and approved the final draft of the manuscript.
: Not applicable.
: Not applicable.